Semin Respir Crit Care Med 2022; 43(05): 627-634
DOI: 10.1055/s-0042-1753486
Review Article

Current Biologics in Asthma Treatment

Donya Imanirad
1   Department of Allergy, Immunology, Morsani College of Medicine, University of South Florida, Tampa, Florida
,
Farnaz Tabatabaian
2   Division of Allergy and Immunology in Medicine and Pediatrics, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida
› Author Affiliations

Abstract

Uncontrolled asthma and/or severe asthma causes significant impairments in quality of life and is often a huge health care burden. Monoclonal antibodies have been an important addition to the therapeutic management of patients with moderate to severe asthma who do not respond to conventional asthma management. Currently the majority of Food and Drug Administration (FDA) approved biologics target T2 high inflammation. However, with the expanding knowledge of asthma pathogenesis, novel therapeutics targeting T2 low inflammation are in development. In this article we will focus on the current understanding of T2 inflammation and approved biologics for moderate to severe asthma.



Publication History

Article published online:
11 October 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Boonpiyathad T, Sözener ZC, Satitsuksanoa P, Akdis CA. Immunologic mechanisms in asthma. Semin Immunol 2019; 46: 101333
  • 2 Jones TL, Neville DM, Chauhan AJ. Diagnosis and treatment of severe asthma: a phenotype-based approach. Clin Med (Lond) 2018; 18 (Suppl. 02) s36-s40
  • 3 Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 2019; 56 (02) 219-233
  • 4 Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract 2014; 2 (06) 671-680 , quiz 681
  • 5 Yancey SW, Keene ON, Albers FC. et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol 2017; 140 (06) 1509-1518
  • 6 Kumar C, Zito PM. Omalizumab. StatPearls. Treasure Island, FL: StatPearls Publishing Copyright; 2022
  • 7 McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs 2013; 73 (11) 1197-1212
  • 8 Hanania NA, Alpan O, Hamilos DL. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154 (09) 573-582
  • 9 Humbert M, Busse W, Hanania NA. et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014; 2 (05) 525-36.e1
  • 10 Busse WW, Kraft M, Rabe KF. et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J 2021; 58 (02) 2003393
  • 11 Brusselle G, Michils A, Louis R. et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103 (11) 1633-1642
  • 12 Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 79 (12) 3101-3109
  • 13 Ridolo E, Pucciarini F, Nizi MC. et al. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother 2020; 16 (10) 2349-2356
  • 14 Pavord ID, Korn S, Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380 (9842): 651-659
  • 15 Ortega HG, Liu MC, Pavord ID. et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371 (13) 1198-1207
  • 16 Bel EH, Wenzel SE, Thompson PJ. et al; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371 (13) 1189-1197
  • 17 Fala L. Nucala (Mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits 2016; 9 (Spec Feature): 106-110
  • 18 Haldar P, Brightling CE, Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360 (10) 973-984
  • 19 Han JK, Bachert C, Fokkens W. et al; SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9 (10) 1141-1153
  • 20 Common Drug Reviews CADTH. Reslizumab (Cinqair). Ottawa, ON: Canadian Agency for Drugs and Technologies in Health Copyright © CADTH 2017; 2017
  • 21 Castro M, Mathur S, Hargreave F. et al; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184 (10) 1125-1132
  • 22 Hom S, Pisano M. Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. P&T 2017; 42 (09) 564-568
  • 23 Mukherjee M, Aleman Paramo F, Kjarsgaard M. et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med 2018; 197 (01) 38-46
  • 24 Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol 2019; 29 (02) 84-93
  • 25 FitzGerald JM, Bleecker ER, Nair P. et al; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2128-2141
  • 26 Bleecker ER, FitzGerald JM, Chanez P. et al; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388 (10056): 2115-2127
  • 27 Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019; 15 (09) 2129-2139
  • 28 Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol 2018; 28 (03) 139-150
  • 29 M Walsh GG MW. Dupilumab utility in difficult-to-treat asthma. Immunotherapy 2019; 11 (04) 261-264
  • 30 Wu AY, Sur S, Grant JA, Tripple JW. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma. Curr Opin Allergy Clin Immunol 2019; 19 (01) 30-37
  • 31 Busse WW, Maspero JF, Lu Y. et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol 2020; 125 (05) 565-576.e561
  • 32 Rabe KF, Nair P, Brusselle G. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378 (26) 2475-2485
  • 33 Mitchell PD, O'Byrne PM. Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma. Pharmacol Ther 2017; 169: 104-112
  • 34 Ying S, O'Connor B, Ratoff J. et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol 2008; 181 (04) 2790-2798
  • 35 Lee HC, Headley MB, Loo YM. et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012; 130 (05) 1187-1196.e5
  • 36 Indra AK. Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis. Expert Rev Proteomics 2013; 10 (04) 309-311
  • 37 Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008; 9 (03) 310-318
  • 38 Pelaia C, Pelaia G, Crimi C. et al. Tezepelumab: a potential new biological therapy for severe refractory asthma. Int J Mol Sci 2021; 22 (09) 4369
  • 39 Tan R, Liew MF, Lim HF, Leung BP, Wong WSF. Promises and challenges of biologics for severe asthma. Biochem Pharmacol 2020; 179: 114012
  • 40 Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy 2021; 14: 1-11
  • 41 Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract 2017; 5 (04) 909-916
  • 42 Essilfie AT, Horvat JC, Kim RY. et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015; 70 (05) 458-467
  • 43 Pepper AN, Hanania NA, Humbert M, Casale TB. How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. J Allergy Clin Immunol Pract 2021; 9 (03) 1081-1088
  • 44 Busse W, Corren J, Lanier BQ. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108 (02) 184-190
  • 45 Dorey-Stein ZL, Shenoy KV. Tezepelumab as an emerging therapeutic option for the treatment of severe asthma: evidence to date. Drug Des Devel Ther 2021; 15: 331-338
  • 46 Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; (01) CD003559
  • 47 Humbert M, Beasley R, Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60 (03) 309-316
  • 48 Milgrom H, Berger W, Nayak A. et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108 (02) E36
  • 49 Chupp GL, Bradford ES, Albers FC. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5 (05) 390-400
  • 50 Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 2017; 9 (09) CD010834
  • 51 Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016; 150 (04) 789-798
  • 52 Nair P, Wenzel S, Rabe KF. et al; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376 (25) 2448-2458
  • 53 Castro M, Corren J, Pavord ID. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378 (26) 2486-2496